Clozapine

Strong CYP3A4 inducer that decreases clozapine plasma concentration. Concomitant use is not recommended due to decreased clozapine effectiveness.

Concomitant use may produce marked sedation, excessive salivation, hypotension, ataxia, delirium, and respiratory arrest.

Strong CYP3A4 inducer that decreases clozapine plasma concentration. Concomitant use is not recommended due to decreased clozapine effectiveness.

Strong CYP3A4 inducer that decreases clozapine plasma concentration. Concomitant use is not recommended due to decreased clozapine effectiveness.

Strong CYP3A4 inducer that decreases clozapine plasma concentration. Concomitant use is not recommended due to decreased clozapine effectiveness.

Strong CYP1A2 inhibitor that increases clozapine plasma levels, potentially resulting in adverse reactions. Requires dose reduction to one-third.

Strong CYP1A2 inhibitor that increases clozapine plasma levels, potentially resulting in adverse reactions. Requires dose reduction to one-third.

Potential for elevation of clozapine levels with risk of toxicity.

Strong CYP1A2 inhibitor that increases clozapine plasma levels, potentially resulting in adverse reactions. Requires dose reduction to one-third.

May decrease blood glucose lowering effect of LANTUS. Dosage increases and increased glucose monitoring may be required.

CYP2D6 or CYP3A4 inhibitor that can increase clozapine levels and lead to adverse reactions. Close monitoring and dose reduction may be necessary.

Moderate or weak CYP1A2 inhibitor that may increase clozapine levels. Monitor patients closely and consider dose reduction if necessary.

CYP2D6 or CYP3A4 inhibitor that can increase clozapine levels and lead to adverse reactions. Close monitoring and dose reduction may be necessary.

CYP2D6 or CYP3A4 inhibitor that can increase clozapine levels and lead to adverse reactions. Close monitoring and dose reduction may be necessary.

CYP2D6 or CYP3A4 inhibitor that can increase clozapine levels and lead to adverse reactions. Close monitoring and dose reduction may be necessary.

CYP2D6 or CYP3A4 inhibitor that can increase clozapine levels and lead to adverse reactions. Close monitoring and dose reduction may be necessary.

Potential for elevation of clozapine levels.

Atypical antipsychotic that may reduce glucose-lowering effect of glimepiride, leading to worsening glycemic control.

May reduce glucose-lowering effect of glipizide, leading to worsening glycemic control; monitor closely.

Atypical antipsychotic that may decrease the blood glucose lowering effect. Dose adjustment and increased glucose monitoring required.

May decrease blood glucose lowering effect. Dose adjustment and increased glucose monitoring may be required.

Atypical antipsychotic that may decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.

Atypical antipsychotic that may decrease blood glucose-lowering effect; dosage increases and increased glucose monitoring may be required.

May decrease blood glucose lowering effect of insulin detemir. Dosage increases and increased glucose monitoring may be required.

Atypical antipsychotic that may decrease the blood glucose lowering effect. Dose increases and increased glucose monitoring may be required.

Atypical antipsychotic that may decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.

Atypical antipsychotic that may decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.

Atypical antipsychotic that may decrease blood glucose lowering effect; dose adjustment and increased glucose monitoring may be required.

May decrease blood glucose lowering effect of Awiqli. Dose increases and increased glucose monitoring may be required.

Atypical antipsychotic that may decrease blood glucose lowering effect; dose adjustment and increased glucose monitoring required.

Atypical antipsychotic that may decrease blood glucose lowering effect. Dose increases and increased glucose monitoring may be required.

May elevate clozapine levels.

Moderate or weak CYP1A2 inhibitor that may increase clozapine levels. Monitor patients closely and consider dose reduction if necessary.

CYP2D6 or CYP3A4 inhibitor that can increase clozapine levels and lead to adverse reactions. Close monitoring and dose reduction may be necessary.

CYP2D6 or CYP3A4 inhibitor that can increase clozapine levels and lead to adverse reactions. Close monitoring and dose reduction may be necessary.

Atypical antipsychotic that may decrease blood glucose lowering effect. Repaglinide dose increases and increased glucose monitoring may be required.

Chronic administration of clozapine may decrease the clearance of risperidone.

CYP2D6 or CYP3A4 inhibitor that can increase clozapine levels and lead to adverse reactions. Close monitoring and dose reduction may be necessary.

CYP2D6 or CYP3A4 inhibitor that can increase clozapine levels and lead to adverse reactions. Close monitoring and dose reduction may be necessary.

Moderate CYP1A2 inducer that can decrease clozapine plasma concentration. Consider increasing clozapine dose or monitoring closely.

Suspected of causing diabetes insipidus; may decrease pressor and antidiuretic effects of vasopressin. Hemodynamic monitoring recommended.

May cause diabetes insipidus, decreasing pressor and antidiuretic effects of vasopressin. Hemodynamic monitoring recommended; adjust vasopressin dose as needed.

Drugs that cause QT prolongation include: specific antipsychotics (e.g., ziprasidone, iloperidone, chlorpromazine, thioridazine, mesoridazine, droperidol, and pimozide), specific antibiotics (e.g., erythromycin, gatifloxacin, moxifloxacin, sparfloxacin), Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class III antiarrhythmics (e.g., amiodarone, sotalol), and others (e.g., pentamidine, levomethadyl acetate, methadone, halofantrine, mefloquine, dolasetron mesylate, probucol or tacrolimus) [see Warnings and Precautions (5.9) ] .

Drugs that cause QT prolongation include: specific antipsychotics (e.g., ziprasidone, iloperidone, chlorpromazine, thioridazine, mesoridazine, droperidol, and pimozide), specific antibiotics (e.g., erythromycin, gatifloxacin, moxifloxacin, sparfloxacin), Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class III antiarrhythmics (e.g., amiodarone, sotalol), and others (e.g., pentamidine, levomethadyl acetate, methadone, halofantrine, mefloquine, dolasetron mesylate, probucol or tacrolimus) [see Warnings and Precautions (5.9) ] .

Drugs that cause QT prolongation include: specific antipsychotics (e.g., ziprasidone, iloperidone, chlorpromazine, thioridazine, mesoridazine, droperidol, and pimozide), specific antibiotics (e.g., erythromycin, gatifloxacin, moxifloxacin, sparfloxacin), Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class III antiarrhythmics (e.g., amiodarone, sotalol), and others (e.g., pentamidine, levomethadyl acetate, methadone, halofantrine, mefloquine, dolasetron mesylate, probucol or tacrolimus) [see Warnings and Precautions (5.9) ] .

Drugs that cause QT prolongation include: specific antipsychotics (e.g., ziprasidone, iloperidone, chlorpromazine, thioridazine, mesoridazine, droperidol, and pimozide), specific antibiotics (e.g., erythromycin, gatifloxacin, moxifloxacin, sparfloxacin), Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class III antiarrhythmics (e.g., amiodarone, sotalol), and others (e.g., pentamidine, levomethadyl acetate, methadone, halofantrine, mefloquine, dolasetron mesylate, probucol or tacrolimus) [see Warnings and Precautions (5.9) ] .